Zafgen Announces Departure of President and Chief Scientific Officer Dr. Thomas Hughes
August 02, 2018 16:05 ET
|
Zafgen, Inc.
BOSTON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected...
Zafgen to Present at the Canaccord Genuity 38th Annual Growth Conference
August 01, 2018 16:15 ET
|
Zafgen, Inc.
BOSTON, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen to Host Conference Call to Discuss Second Quarter 2018 Financial Results
July 31, 2018 16:05 ET
|
Zafgen, Inc.
BOSTON, July 31, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen and the Foundation for Prader-Willi Research Announce PATH for PWS Natural History Study
July 09, 2018 08:00 ET
|
Zafgen, Inc.
Information and data from study will advance understanding of medical history and medical events in people with PWS People living with PWS ages 5 and older and their caregivers are encouraged to...
Zafgen Announces Closing of Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Common Shares
July 02, 2018 16:05 ET
|
Zafgen, Inc.
BOSTON, July 02, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for...
Zafgen Announces Pricing of Offering of Common Stock
June 28, 2018 08:00 ET
|
Zafgen, Inc.
BOSTON, June 28, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for...
Zafgen Announces Proposed Offering of Common Stock
June 27, 2018 16:01 ET
|
Zafgen, Inc.
BOSTON, June 27, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for...
Zafgen Set to Join Russell 3000® Index
June 25, 2018 07:05 ET
|
Zafgen, Inc.
BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for...
REMINDER: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call
June 25, 2018 07:00 ET
|
Zafgen, Inc.
BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected...
Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
June 23, 2018 10:00 ET
|
Zafgen, Inc.
Trial met all primary objectives, demonstrated efficacy and safety and established minimally effective dose of 0.9 mg for ZGN-1061 Patient dosing recently initiated for the 1.8 mg dose cohort Zafgen...